Idience is a science-driven biopharmaceutical company focused on improving the quality of life for oncology patients. Operating in the biopharmaceutical sector, Idience specializes in the development of PARP inhibitors, which are a class of drugs used in cancer treatment. The company serves patients, healthcare providers, and research institutions by conducting clinical trials and developing innovative therapies aimed at combating cancer. Idience's business model revolves around extensive research and development (R&D), clinical trials, and eventual commercialization of its proprietary drugs. Revenue is primarily generated through the sale of these specialized oncology medications and potential partnerships or licensing agreements with larger pharmaceutical companies. The company is headquartered in San Francisco, California, and is committed to transforming scientific discoveries into practical medical solutions.

Keywords: biopharmaceutical, oncology, PARP inhibitors, cancer treatment, clinical trials, R&D, healthcare, innovation, San Francisco, quality of life.